OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZURES AGED FROM 1 MONTH TO <2 YEARS

Trial Profile

OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZURES AGED FROM 1 MONTH TO <2 YEARS

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Pharmacokinetics
  • Sponsors Bial
  • Most Recent Events

    • 04 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top